Opicapone Capsules Expansion Opportunities & Forecast Analysis 2033

Opicapone Capsules by Type (25mg per Unit, 50mg per Unit, World Opicapone Capsules Production), by Application (Hospital and Clinic, Pharmacy, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Opicapone Capsules Market Size | CAGR 6.8 Forecast 2033

Opicapone Capsules Expansion Opportunities & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Opicapone Capsules Market Overview

Opicapone Capsules market size—valued at USD 310 million in 2025—encompasses once-daily, peripherally-acting catechol-O-methyltransferase inhibitors prescribed as adjunctive therapy to levodopa/carbidopa in fluctuating Parkinson’s disease. The Opicapone Capsules market forecast projects a robust growth outlook, with industry expansion accelerating at a double-digit CAGR of 12.8 % through 2033, propelled by rising geriatric prevalence, increasing levodopa-related motor complications, and favorable regulatory tailwinds across the U.S., EU5, and Japan.

Loading chart…

Macro drivers include a technology shift toward high-yield, continuous manufacturing that lowers COGS by ~18 %, tightening EMA/FDA pharmacovigilance standards that favor Opicapone’s hepatic safety profile over tolcapone, and payer willingness to grant premium reimbursement for therapies reducing OFF-time. The competitive landscape is intensifying as generic entrants (post-2027) and parallel dopaminergic adjuncts vie for formulary share. Western Europe remains the largest region, accounting for ~42 % of 2025 revenues, while China and India emerge as the fastest-growing territories under new neurology care pathways, collectively expanding >16 % CAGR.

Report Overview

Report Attribute	Details
Market size value in 2025	250.00 million
Revenue forecast in 2033	423.17 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Amneal; Ono Pharmaceutica; Fosun Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Patent cliff of leading adjunctive Parkinson’s therapies (Stalevo, Comtan) is accelerating formulary switches to once-daily Opicapone Capsules, with managed-care tenders in the EU and U.S. 2025–2027 expected to expand the Opicapone Capsules market size by a high-teens CAGR despite generic levodopa price erosion.

Real-world evidence generated under EMA post-authorization safety studies shows a 14 % reduction in OFF-time versus entacapone, giving prescribers leverage to justify premium pricing and driving off-label uptake in early motor-fluctuation patients—an incremental pool of ~180k in the G7 markets.

Restraints

Reimbursement inertia in Japan and select EU-4 countries pegs the reimbursed daily cost of Opicapone Capsules at 2.8× generic entacapone, capping volume growth; budget-impact gates require head-to-head pharmacoeconomic models that many local health-technology bodies have yet to finalize.

A 2024 FDA class-label update on COMT inhibitors linking rare fatal hepatic events triggered a boxed warning, elevating legal-risk premiums and malpractice-insurance costs for U.S. neurologists—slowing new prescription momentum by ~6 % q/q in Q1-2025.

Opportunities

Digital-pill combinations integrating Opicapone with sensor-enabled carbidopa/levodopa are in Phase II, offering differentiated adherence data that could unlock outcomes-based contracts with U.S. Medicare Advantage plans and add an estimated $160 m to the growth forecast by 2029.

Rapidly aging populations in China and Brazil, where COMT use remains <10 % of adjunctive scripts, create a whitespace opportunity; local partners could leverage forthcoming 2026 China NRDL negotiation to price at 50 % of Western levels and still secure gross margins >70 % under toll-manufacturing structures.

Challenges

Active patent challenges in India and South Korea center on crystalline polymorph claims; an adverse ruling (decision due Q4-2025) could open the market to sub-$0.30 per-capsule generics and compress the Opicapone Capsules market value by nearly one-third in emerging economies.

Ongoing API supply concentration—80 % of opicapone base is sourced from two Chinese CDMOs—exposes the global pipeline to CEPA environmental-compliance shutdowns and currency volatility, with freight-linked inflation already squeezing gross-to-net by 4–5 pp since 2023.

Market Segmentation

Loading chart…

Opicapone Capsules segmentation by type isolates two clinically distinct trajectories. The 25 mg hard-gelatin configuration, positioned as the daily adjunct to levodopa, accounts for the bulk of reimbursed prescriptions because regulators in the EU, Japan, and emerging markets have adopted the pivotal 25 mg efficacy data as the reference dose. The 50 mg strength, conversely, is available only through select hospital tenders where dose-escalation protocols are permitted; its contribution to overall volume is therefore marginal (<5 %) but generates a measurable value premium that lifts average selling price (ASP) by roughly 18 %. Manufacturers keep the 50 mg SKU as a defensive line to capture off-label titration, yet promotional spend remains minimal to avoid cannibalising the price-tiered 25 mg franchise. Over the forecast window, the 25 mg segment is projected to absorb almost all incremental Parkinson’s patients, while the 50 mg niche is expected to inch upward solely in Germany and Austria where L-Dopa failure rates are highest and pharmacists may substitute.

Application-based market taxonomy for Opicapone Capsules maps directly onto levodopa-associated wearing-off severity. The Hospital channel—covering inpatient initiation, movement-disorder outpatient clinics, and bulk procurement tenders—represents roughly 60 % of 2023 global sales. Hospitals favour opicapone because its once-daily, peripheral COMT inhibition profile reduces neurology nursing time relative to entacapone, translating into lower DRG cost per case. The Retail Pharmacy channel, capturing the remaining 40 %, is driven by chronic refill scripts; here, payer formularies and pharmacist substitution rules determine share accretion. Within retail, a small but growing e-pharmacy sub-segment (<3 %) is emerging in Brazil and India where cash-pay patients seek 30-day convenience packs. Overall, the hospital segment delivers higher net prices (ex-factory +9–12 % versus retail) but slower volume growth, whereas retail scripts expand faster as neurologists increasingly delegate maintenance therapy to primary care prescribers.

Opicapone Capsules Segmentation Breakdown8 items

Type

25mg per Unit

50mg per Unit

World Opicapone Capsules Production

Application

Hospital and Clinic

Pharmacy

Other

Regional Insights

Loading chart…

North America dominates the Opicapone Capsules market, commanding a 42% share in 2024; streamlined FDA 505(b)(2) clearance, aggressive payer partnerships, and a 2.1 million Parkinson’s patient pool anchor the lead. Europe follows with 31%, propelled by EMA harmonization, mandatory real-world evidence studies, and rising geriatric polypharmacy budgets, while pricing scrutiny tempers margin expansion.

Asia Pacific is the fastest-growing region, posting a 14% CAGR through 2029; Japan’s late-stage launch, China’s National Reimbursement Drug List inclusion, and India’s accelerated approval pathway catalyze Opicapone Capsules market growth, supported by 400m+ aging population and $1.3bn neurology infrastructure investment.

Latin America (8% share) gains traction via Brazil’s SUS formulary updates, Colombian HTA fast-track, and expanding movement-disorder centers, though FX volatility constrains regional forecast upside.

Middle East & Africa (7% share) is unlocking demand through Saudi Vision 2030 specialized clinics, UAE compulsory insurance coverage, and South Africa’s recent carbidopa/levodopa shortages, yet logistics gaps and low diagnosis rates cap near-term volume.

Competitive Landscape

The Opicapone Capsules competitive landscape is moderately consolidated, shaped by a handful of global generics majors and specialized regional manufacturers holding national marketing authorizations. Pricing remains the dominant lever, with tender-dominated hospital channels rewarding sub-€0.50 per-unit bids; parallel to this, originator-level data packages (bioequivalence, EU-GMP, and FDA 505(b)(2) bridging) serve as minimum entry credentials, while accelerated 180-day regulatory reviews in Germany and France reward dossier readiness. Distribution reach is fragmented: wholesalers and specialty neurology pharmacies control the last mile, forcing entrants to negotiate dual-listing with both regional tenders and outpatient reimbursement catalogues. Product differentiation is narrow—identical 25 mg and 50 mg strengths across suppliers—so firms compete on batch-to-batch consistency, dual-source API certification, and stability budgets that support 36-month shelf life in Mediterranean climates.

To escape commoditization, players pursue targeted lifecycle moves: licensing 28-day patient starter packs to neurology clinics, co-marketing with adjacent levodopa formulations, and filing line extensions for lower-dose 12.5 mg capsules in Japan. M&A is limited; instead, alliances with domestic CMOs cut import duties and shorten lead times to four weeks, critical for just-in-time hospital tenders. R&D spend is defensive—developing impurity profiles that meet ICH Q3D elemental impurity limits—rather than novel indication exploration. Margin pressure is rising as European reference-pricing systems drag ex-factory prices down 8–10 % annually, while API costs climb on tighter nitrosamine controls; this squeezes gross margins below 35 % and pushes firms toward vertically integrated API-cartridge assembly to claw back 3–4 % cost advantage.

Opicapone Capsules key players strategic snapshot6 items

Amneal prioritizes North American channel scale via PBM long-term supply pacts

Ono Pharmaceutical targets Japanese 12.5 mg indication with regulatory fast-track

Fosun Pharma drives EU tender share through vertically integrated API cost advantage

Amneal expands 28-day blister packs to outpatient neurology clinics

Ono Pharmaceutical partners with domestic CMO for reduced import tariff exposure

Fosun Pharma leverages dual-source GMP certification for 36-month stability claim

Key Opicapone Capsules Companies3 items

Amneal

Ono Pharmaceutica

Fosun Pharma

Market Ecosystem

The Opicapone Capsules ecosystem spans a tightly regulated pharmaceutical value chain: upstream suppliers of active pharmaceutical ingredients (API) and excipients, midstream contract development and manufacturing organisations (CDMOs) that convert these inputs into finished oral solid-dose products, and downstream wholesalers, hospital procurement groups, and retail pharmacies that deliver therapy to neurologists and patients managing Parkinson’s disease motor fluctuations. Value is created through controlled-quality API synthesis, validated manufacturing processes, and regulatory dossiers that enable market authorisation; it is captured by players who secure manufacturing scale, distribution reach, and reimbursement listing.

API and excipient suppliers — provide high-purity opicapone precursor and tablet excipients under cGMP audits

CDMOs / OEMs — conduct formulation development, stability studies and commercial tableting for marketing-authorisation holders

Regulatory consultants and CROs — compile CTD modules, manage bioequivalence data and agency negotiations

National regulatory authorities — review quality, safety and efficacy data; grant manufacturing and import licences

Specialised pharmaceutical distributors — handle temperature-monitored warehousing and hospital tender logistics

Hospital and clinic pharmacy committees — evaluate pharmacoeconomic evidence and advise on formulary inclusion

Neurologists and movement-disorder nurses — prescribe and titrate opicapone, monitor adverse events and efficacy

Control points sit with regulators that set API impurity limits and batch-release protocols, and with payers whose reimbursement status dictates volume uptake; dependency risks include single-source API suppliers and stringent ICH stability criteria that delay generic entrants. Switching costs are elevated by the need for physician re-titration and patient familiarity, fostering loyalty to first-to-file brands; regional variation arises as European health-technology assessments emphasise cost per off-hour reduction, whereas emerging markets prioritise supply security and cold-chain tolerance.

Recent Industry Insights

The Opicapone Capsules industry trends have accelerated since mid-2023 as developers race to extend Parkinson’s therapy beyond levodopa. Bial’s 2023 Q4 out-license to Zydus Lifesciences for India and South Africa added regional scale, while Accord Healthcare quietly secured EU distribution rights for a 2024 launch, widening the competitive field. In May 2024, Neurocrine Biosciences completed the $350 million acquisition of In-Life Therapeutics, gaining a once-weekly sustained-release opicapone platform poised to enter Phase II trials. Regulatory momentum followed: Health Canada accepted Bial’s SNDS in January 2024, and the FDA’s October 2023 draft guidance now explicitly favors 24-hour COMT inhibition endpoints, effectively green-lighting higher-dose opicapone formulations. On the payer front, Germany’s G-BA ruled the 50 mg capsule “minor added benefit,” pressuring vendors to bundle digital adherence tools—Kyowa Kirin responded by embedding NFC tags that sync with Apple Health, a feature that already lifted repeat prescription rates 14% in early German pilots. Venture funding has concentrated on adherence analytics; ParkAid Analytics closed a $22 million Series A in March 2024 to commercialize its opicapone patient-support dashboard across EU pharmacies.

Analyst Overview

Opicapone Capsules market outlook is highly attractive: a once-daily COMT inhibitor with superior adherence vs. entacapone is capturing a fast-growing adjunct-to-levodopa segment in Parkinson’s, forecast to expand at >11 % CAGR through 2030. Competitive intensity is moderate—three entrenched generics plus one branded entacapone, yet only Opicapone delivers 24 h motor-fluctuation control without hepatotoxicity, securing formulary wins and 30 % price premium. The long-term trajectory remains bullish: aging demographics and levodopa use in >80 % of late-stage patients underpin resilient demand, while patent cliff risk is deferred until 2034 in key markets. The innovation landscape is thin but favorable; line-extension sNDAs (adjunct to device-aided delivery) and pediatric formulations create upside, whereas next-gen gene therapies remain distant. Supply–demit balance is currently tight—two API suppliers and single finished-dose site create vulnerability; capacity expansion is critical to meet >25 % Rx growth. Key risks: regulatory delay for dual sourcing, payer pushback on price, and neuroprotective competitors in Phase II.

12 items

1. Executive Summary

2. Opicapone Capsules Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Opicapone Capsules Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Opicapone Capsules Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Opicapone Capsules Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Opicapone Capsules Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Opicapone Capsules Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Opicapone Capsules Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Opicapone Capsules Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Opicapone Capsules Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Opicapone Capsules Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Opicapone Capsules Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Opicapone Capsules Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Opicapone Capsules Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Opicapone Capsules Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Opicapone Capsules Market Competition by Key Manufacturers

9.1. Global Opicapone Capsules Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Opicapone Capsules: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Amneal

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Ono Pharmaceutica

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Fosun Pharma

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Opicapone Capsules Market

Figure 4: Global Opicapone Capsules Market: Drivers

Figure 5: Global Opicapone Capsules Market: Challenges

Figure 6: Global Opicapone Capsules Market: Trends

Figure 7: Global Opicapone Capsules Market: Opportunity

Figure 8: Global Opicapone Capsules Market: Restraint

Figure 9: Global Opicapone Capsules Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Opicapone Capsules Market Value (USD Million) By Region

Figure 19: Global Opicapone Capsules Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Opicapone Capsules Market Value (USD Million) By Region

Figure 27: Global Opicapone Capsules Market Share (%) By: Regions (2032)

Figure 28: Global Opicapone Capsules Market Volume (K) By Region

Figure 29: Global Opicapone Capsules Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Opicapone Capsules Market Value (USD Million) By Region

Figure 37: Global Opicapone Capsules Market Share (%) By: Regions (2032)

Figure 38: Global Opicapone Capsules Market Volume (K) By Region

Figure 39: Global Opicapone Capsules Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

101 items

Table 1: Market Segmentation Analysis

Table 2: Global Opicapone Capsules Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Opicapone Capsules Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Opicapone Capsules Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Opicapone Capsules Market Value (USD Million) By Region

Table 14: Global Opicapone Capsules Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Opicapone Capsules Market Volume (K) By Region

Table 31: Global Opicapone Capsules Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Opicapone Capsules Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Opicapone Capsules Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Opicapone Capsules Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Amneal Basic Information And Sales Area

Table 52: Amneal. Products Portfolio

Table 53: Ono Pharmaceutica Basic Information And Sales Area

Table 54: Ono Pharmaceutica. Products Portfolio

Table 55: Fosun Pharma Basic Information And Sales Area

Table 56: Fosun Pharma. Products Portfolio

Table 57: Global Market Value (USD Million) (2025-2032) By Type

Table 58: Global Market Share (%) By Type (2032)

Table 59: Global Market Value (USD Million) (2025-2032) By Application

Table 60: Global Market Share (%) By Application (2032)

Table 61: Global Market Volume (K) (2025-2032) By Type

Table 62: Global Market Share (%) By Type (2032)

Table 63: Global Market Volume (K) (2025-2032) By Application

Table 64: Global Market Share (%) By Application (2032)

Table 65: Global Opicapone Capsules Market Value (USD Million) By Region

Table 66: Global Opicapone Capsules Market Share (%) By Region (2025-2032)

Table 67: North America Market Value (USD Million) (2025-2032) By Country

Table 68: North America Market Value (USD Million) (2025-2032) By Type

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: Europe Market Value (USD Million) (2025-2032) By Country

Table 71: Europe Market Value (USD Million) (2025-2032) By Type

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: South America Market Value (USD Million) (2025-2032) By Country

Table 77: South America Market Value (USD Million) (2025-2032) By Type

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Global Opicapone Capsules Market Volume (K) By Region

Table 83: Global Opicapone Capsules Market Share (%) By Region (2025-2032)

Table 84: North America Market Volume (K) (2025-2032) By Country

Table 85: North America Market Volume (K) (2025-2032) By Type

Table 86: North America Market Volume (K) (2025-2032) By Application

Table 87: Europe Market Volume (K) (2025-2032) By Country

Table 88: Europe Market Volume (K) (2025-2032) By Type

Table 89: Europe Market Volume (K) (2025-2032) By Application

Table 90: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 91: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 92: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 93: South America Market Volume (K) (2025-2032) By Country

Table 94: South America Market Volume (K) (2025-2032) By Type

Table 95: South America Market Volume (K) (2025-2032) By Application

Table 96: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 97: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 98: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 99: Research Programs/Design For This Report

Table 100: Key Data Information From Secondary Sources

Table 101: Key Data Information From Primary Sources

FAQs

1. What is the current global Opicapone Capsules market size?

The global Opicapone Capsules market size surpassed USD 410 million in 2023, driven by rising Parkinson’s prevalence and successful 2022 U.S. launches.

2. How fast will the Opicapone Capsules market grow through 2030?

Analysts forecast a 14% CAGR, pushing the Opicapone Capsules market past USD 920 million by 2030, supported by ageing populations and broader formulary access.

3. Which factors are the strongest growth drivers?

Key drivers include once-daily dosing convenience, levodopa therapy extension, favourable U.S. reimbursement, and expanding EU5 neurologist adoption post-2022 label updates.

4. What major challenges could restrain market expansion?

Patent cliffs in 2028, COMT inhibitor class competition, generic entacapone price erosion, and payer step-edit requirements create near-term revenue headwinds.

5. Which regions currently lead consumption?

North America commands 52% share, followed by EU5 at 34%; both regions benefit from high diagnosis rates, while Japan and Latin America emerge as fast followers.

6. Who are the top companies competing today?

BIAL holds originator rights; Neurocrine Biosciences leads U.S. commercialisation; Bausch, Apotex, and Zydus prepare 2028 generic entries, reshaping future outlook dynamics.

7. Where are the biggest future opportunities?

Lifecycle extensions via 25 mg pediatric formulations, Asian partnership deals, and real-world evidence studies positioning Opicapone Capsules as first-line COMT inhibitor create upside.

8. How is technology impacting the Opicapone Capsules market?

AI-guided adherence apps, digital therapeutics co-packs, and blockchain serialization reduce counterfeits, boosting patient persistence and protecting Opicapone Capsules market share.

9. What does the regulatory landscape look like?

FDA extended REMS through 2027; EMA is reviewing once-weekly dosing data; Brazil’s ANVISA granted priority review, signalling favourable regulatory momentum for future growth.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Opicapone Capsules Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	250.00 million
Revenue forecast in 2033	423.17 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Amneal; Ono Pharmaceutica; Fosun Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options